Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inogen, Inc stock logo
INGN
Inogen
$5.64
-1.0%
$6.00
$5.05
▼
$7.67
$146.91M1.51297,392 shs200,781 shs
Myomo, Inc. stock logo
MYO
Myomo
$1.04
-15.9%
$1.37
$0.61
▼
$1.89
$41.50M1.74532,657 shs581,568 shs
Neuronetics, Inc. stock logo
STIM
Neuronetics
$1.26
-9.7%
$2.35
$0.80
▼
$3.44
$98.33M1.362.13 million shs4.26 million shs
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
$2.28
-6.2%
$4.05
$2.17
▼
$7.95
$139.47M0.5300,506 shs314,110 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inogen, Inc stock logo
INGN
Inogen
0.00%-5.64%-8.96%-0.35%-17.54%
Myomo, Inc. stock logo
MYO
Myomo
0.00%+1.65%+2.50%-21.66%+50.75%
Neuronetics, Inc. stock logo
STIM
Neuronetics
0.00%-35.35%-26.26%-57.49%-30.15%
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
0.00%-25.23%-33.06%-53.89%-46.71%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inogen, Inc stock logo
INGN
Inogen
$5.64
-1.0%
$6.00
$5.05
▼
$7.67
$146.91M1.51297,392 shs200,781 shs
Myomo, Inc. stock logo
MYO
Myomo
$1.04
-15.9%
$1.37
$0.61
▼
$1.89
$41.50M1.74532,657 shs581,568 shs
Neuronetics, Inc. stock logo
STIM
Neuronetics
$1.26
-9.7%
$2.35
$0.80
▼
$3.44
$98.33M1.362.13 million shs4.26 million shs
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
$2.28
-6.2%
$4.05
$2.17
▼
$7.95
$139.47M0.5300,506 shs314,110 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inogen, Inc stock logo
INGN
Inogen
0.00%-5.64%-8.96%-0.35%-17.54%
Myomo, Inc. stock logo
MYO
Myomo
0.00%+1.65%+2.50%-21.66%+50.75%
Neuronetics, Inc. stock logo
STIM
Neuronetics
0.00%-35.35%-26.26%-57.49%-30.15%
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
0.00%-25.23%-33.06%-53.89%-46.71%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inogen, Inc stock logo
INGN
Inogen
2.50
Moderate BuyN/AN/A
Myomo, Inc. stock logo
MYO
Myomo
3.00
Buy$10.00866.18% Upside
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.67
Moderate Buy$5.00298.41% Upside
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
2.50
Moderate Buy$9.20303.51% Upside

Current Analyst Ratings Breakdown

Latest MYO, TLSI, INGN, and STIM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Neuronetics, Inc. stock logo
STIM
Neuronetics
Initiated CoverageMarket Perform ➝ Outperform
11/11/2026
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
Lower Price TargetBuy$12.00 ➝ $10.00
11/10/2026
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
Reiterated RatingBuy
11/10/2026
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
Lower Price TargetBuy$7.00 ➝ $4.00
11/6/2026
Neuronetics, Inc. stock logo
STIM
Neuronetics
Boost Price TargetBuy$5.00 ➝ $6.00
11/4/2026
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
Reiterated RatingSell (E+)
11/3/2026
Inogen, Inc stock logo
INGN
Inogen
Reiterated RatingSell (D-)
9/23/2026
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
Set Price Target$12.00
9/23/2026
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
Set Price Target$12.00
9/23/2026
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
Boost Price TargetBuy$11.00 ➝ $12.00
9/17/2026
Neuronetics, Inc. stock logo
STIM
Neuronetics
Reiterated RatingBuy$6.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inogen, Inc stock logo
INGN
Inogen
$355.06M0.41N/AN/A$7.08 per share0.80
Myomo, Inc. stock logo
MYO
Myomo
$40.93M1.01N/AN/A$0.30 per share3.45
Neuronetics, Inc. stock logo
STIM
Neuronetics
$149.16M0.65N/AN/A$0.38 per share3.30
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
$46.39M3.03N/AN/A($0.68) per share-3.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inogen, Inc stock logo
INGN
Inogen
-$22.75M-$1.31N/AN/AN/A-10.46%-19.29%-12.02%N/A
Myomo, Inc. stock logo
MYO
Myomo
-$15.57M-$0.23N/AN/AN/A-33.14%-183.47%-36.79%N/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$39M-$0.33N/AN/AN/A-14.45%-102.23%-16.83%N/A
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
-$39.23M-$0.49N/AN/AN/A-56.60%N/A-55.00%N/A

Latest MYO, TLSI, INGN, and STIM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
-$0.1271-$0.15-$0.0229-$0.15$14.02 million$12.88 million
11/9/2026Q3 2026
Myomo, Inc. stock logo
MYO
Myomo
-$0.0780-$0.07+$0.0080-$0.10$11.51 million$12.33 million
11/5/2026Q3 2026
Inogen, Inc stock logo
INGN
Inogen
-$0.1423-$0.56-$0.4177-$0.61$92.25 million$77.19 million
11/4/2026Q3 2026
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.0873-$0.02+$0.0673-$0.02$40.43 million$41.96 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Inogen, Inc stock logo
INGN
Inogen
N/AN/AN/AN/AN/A
Myomo, Inc. stock logo
MYO
Myomo
N/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
N/AN/AN/AN/AN/A
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inogen, Inc stock logo
INGN
Inogen
N/A
2.96
2.55
Myomo, Inc. stock logo
MYO
Myomo
4.24
1.92
1.66
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.76
2.01
1.82
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
47.60
4.22
3.86

Institutional Ownership

CompanyInstitutional Ownership
Inogen, Inc stock logo
INGN
Inogen
89.94%
Myomo, Inc. stock logo
MYO
Myomo
44.99%
Neuronetics, Inc. stock logo
STIM
Neuronetics
53.59%
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
2.58%

Insider Ownership

CompanyInsider Ownership
Inogen, Inc stock logo
INGN
Inogen
2.50%
Myomo, Inc. stock logo
MYO
Myomo
12.14%
Neuronetics, Inc. stock logo
STIM
Neuronetics
8.40%
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
16.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Inogen, Inc stock logo
INGN
Inogen
75326.00 million25.35 millionOptionable
Myomo, Inc. stock logo
MYO
Myomo
19540.10 million35.23 millionNot Optionable
Neuronetics, Inc. stock logo
STIM
Neuronetics
65877.73 million71.20 millionOptionable
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
10261.58 million51.54 millionOptionable

Recent News About These Companies

What is HC Wainwright's Estimate for TLSI FY2026 Earnings?
What is HC Wainwright's Forecast for TLSI FY2026 Earnings?
TriSalus (TLSI) Q3 2026 Earnings Call Transcript
TriSalus Life Sciences Q3 Earnings Call Highlights
TriSalus Life Sciences Reports Third Quarter 2026 Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Inogen stock logo

Inogen NASDAQ:INGN

$5.64 -0.06 (-0.97%)
As of 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

Myomo stock logo

Myomo NYSEAMERICAN:MYO

$1.03 -0.20 (-15.85%)
As of 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, including control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the Veterans Administration, and its distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Neuronetics stock logo

Neuronetics NASDAQ:STIM

$1.25 -0.14 (-9.71%)
As of 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

TriSalus Life Sciences stock logo

TriSalus Life Sciences NASDAQ:TLSI

$2.28 -0.15 (-6.17%)
As of 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.